Literature DB >> 22446338

Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy.

Tatsuo Gondo1, Jun Nakashima, Yoshio Ohno, Ozu Choichiro, Yutaka Horiguchi, Kazunori Namiki, Kunihiko Yoshioka, Makoto Ohori, Tadashi Hatano, Masaaki Tachibana.   

Abstract

OBJECTIVE: Preoperative prognostic factors in bladder cancer patients have not been fully established. This study was undertaken to investigate preoperative prognostic factors, including neutrophil-to-lymphocyte ratio (NLR), and to develop a novel prognostic factors-based risk stratification model for disease-specific survival (DSS) in bladder cancer patients treated with radical cystectomy (RC).
METHODS: We performed a retrospective analysis of 189 consecutive bladder cancer patients treated with RC at our institution. Prognostic value of the preoperative clinical and laboratory parameters were evaluated by univariate and multivariate Cox proportional hazard model analyses, and patients were stratified according to relative risks (RRs) for DSS.
RESULTS: One-, 3-, and 5-year DSS rates were 86.8%, 70.8%, and 61.7%, respectively. In univariate analysis, tumor size, clinical T stage, hydronephrosis, concomitance of carcinoma in situ, and some laboratory findings (hemoglobin [Hb] level, platelet count, C-reactive protein, neutrophil count, lymphocyte count, and NLR) were significantly associated with poor prognosis. In multivariate analysis, tumor size, hydronephrosis, Hb level, and NLR were independent factors for predicting poor prognosis. Patients were stratified into 3 risk groups: low (RR = 1.000-3.717), intermediate (RR = 4.149-9.315), and high (RR = 10.397-38.646). The differences among the groups were significant.
CONCLUSIONS: NLR was an independent prognostic factor, as were tumor size, hydronephrosis, and Hb levels, and the combination of these factors can stratify DSS risks in bladder cancer patients treated with RC. This information may be useful for identifying patients who might be candidates for clinical trials of multimodal treatment strategies, including innovative neoadjuvant treatments.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446338     DOI: 10.1016/j.urology.2011.11.070

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  85 in total

1.  The prognostic role of preoperative circulating neutrophil-lymphocyte ratio in primary bladder cancer patients undergoing radical cystectomy: a meta-analysis.

Authors:  Guoming Hu; Feng Xu; Kefang Zhong; Shimin Wang; Qi Xu; Liming Huang; Pu Cheng
Journal:  World J Urol       Date:  2018-12-03       Impact factor: 4.226

Review 2.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

3.  Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection.

Authors:  Zhangchi Pan; Lu Zhang; Chen Liu; Xiaobing Huang; Songfei Shen; Xiaoyan Lin; Chunmei Shi
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

4.  Exploring the diagnosis markers for gallbladder cancer based on clinical data.

Authors:  Lingqiang Zhang; Runchen Miao; Xiude Zhang; Wei Chen; Yanyan Zhou; Ruitao Wang; Ruiyao Zhang; Qing Pang; Xinsen Xu; Chang Liu
Journal:  Front Med       Date:  2015-07-15       Impact factor: 4.592

5.  The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

Authors:  Richard M Bambury; David J Benjamin; Joshua L Chaim; Emily C Zabor; John Sullivan; Ilana R Garcia-Grossman; Ashley M Regazzi; Irina Ostrovnaya; Aryln Apollo; Han Xiao; Martin H Voss; Gopa Iyer; Dean F Bajorin; Jonathan E Rosenberg
Journal:  Oncologist       Date:  2015-04-06

6.  Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer.

Authors:  Liang Yu; Cheng-Yu Lv; Ai-Hua Yuan; Wei Chen; An-Wei Wu
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

7.  Prognostic value of systemic inflammatory responses in patients with upper urinary tract urothelial carcinoma.

Authors:  Myong Kim; Kyung Chul Moon; Woo Suk Choi; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  World J Urol       Date:  2015-01-20       Impact factor: 4.226

8.  Platelet to lymphocyte ratio plays an important role in prostate cancer's diagnosis and prognosis.

Authors:  Feng Li; Haibo Hu; Shuo Gu; Xin Chen; Qing Sun
Journal:  Int J Clin Exp Med       Date:  2015-07-15

9.  Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.

Authors:  Ahmet Taner Sümbül; Ahmet Sezer; Hüseyin Abalı; Fatih Köse; Ilhami Gültepe; Hüseyin Mertsoylu; Sadık Muallaoğlu; Özgür Özyılkan
Journal:  Int Urol Nephrol       Date:  2014-02-13       Impact factor: 2.370

10.  Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.

Authors:  Mairéad G McNamara; Zarnie Lwin; Haiyan Jiang; Arnoud J Templeton; Gelareh Zadeh; Mark Bernstein; Caroline Chung; Barbara-Ann Millar; Normand Laperriere; Warren P Mason
Journal:  J Neurooncol       Date:  2014-01-28       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.